- Category: HIV Treatment
- Published on Thursday, 07 August 2014 00:00
- Written by Gregory Fowler
Cal Cohen of the Community Research Initiative of New England sat down with HIVandHepstitis.com to offer his summary of some of the highlights of HIV treatment and prevention research presented at the 20th International AIDS Conference last month in Melbourne, Australia.
Cal Cohen, AIDS 2014, Melbourne, July 24, 2014
"There are 10 great [antiretroviral] regimens to choose from," but there's "still lots of discussion and lots of debate" about the best option for specific individuals, Cohen said.
For the first time, guidelines now include a 2-drug regimen -- a protease inhibitor plus a single nucleoside reverse transcriptase inhibitor, lamivudine (3TC, Epivir). But more research is needed on when and for whom this combination might be appropriate.
In terms of prevention, "we're still seeing tens of thousands of new infections in the U.S. alone," and taking antiretrovirals like tenofovir/emtricitabine (Truvada) "if you're negative, to stay negative, is an idea more and more groups are coalescing around," Cohen continued.
"We don't have a cure to look forward to yet...we don't have a vaccine yet that's been proven," he concluded, "but we've got profound progress on treatment [and] profound data on how good treatment is at keeping people well and for controlling and slowing down this epidemic."
C Cohen. 20th International AIDS Conference. Melbourne, July 20-25 2014.